Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.

Cancer prevention research (Philadelphia, Pa.) - 3 Dec 2024

Wu Xingyu, Adame-Garcia Sendi Rafael, Koshizuka Keiichi, Vo Pham Thuy Tien, Hoang Thomas S, Sato Kuniaki, Izumi Hiroki, Goto Yusuke, Allevato Michael M, Wood Kris C, Lippman Scott M, Gutkind Jorge Silvio

Abstract excerpt

Metformin administration has recently emerged as a candidate strategy for the prevention of head and neck squamous cell carcinoma (HNSCC). However, the intricate relationship between genetic alterations in HNSCC and metformin sensitivity is still poorly understood, which prevents the stratification of patients, harboring oral premalignant lesions that may benefit from the chemopreventive activity of metformin. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Glycolysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Metformin

Share to Proto-Oncogene Proteins p21(ras)

Share to Squamous Cell Carcinoma of Head and Neck

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39463147
DOI: 10.1158/1940-6207.CAPR-24-0124
PMCID: PMC11969736

Genes

HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.PMID 39463147Read ↗

Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets.Semantic proximity Read ↗

Targeting the glucose-insulin link in head and neck squamous cell carcinoma induces cytotoxic oxidative stress and inhibits cancer growthSemantic proximity Read ↗

Bioinformatic Analysis of Transcriptome Changes Underlying Metformin-induced Reversal of Drug Resistance in Head and Neck Squamous Cell Carcinoma CellsSemantic proximity Read ↗

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapySemantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targetingSemantic proximity Read ↗

Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.Semantic proximity Read ↗

TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies.Semantic proximity Read ↗

Tumour metabolism in squamous cell carcinoma of the head & neck : consequences & potential therapeutic implications of TP53 mutationSemantic proximity Read ↗

Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.Semantic proximity Read ↗

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.